These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31955599)

  • 1. Low Density Lipoprotein Cholesterol-Lowering Strategies and Population Health: Time to Move to a Cumulative Exposure Model.
    Brandts J; Ray KK
    Circulation; 2020 Mar; 141(11):873-876. PubMed ID: 31955599
    [No Abstract]   [Full Text] [Related]  

  • 2. Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?
    Lloyd-Jones DM
    JAMA Cardiol; 2017 Sep; 2(9):937-938. PubMed ID: 28768306
    [No Abstract]   [Full Text] [Related]  

  • 3. Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
    Hovingh GK; Lepor NE; Kallend D; Stoekenbroek RM; Wijngaard PLJ; Raal FJ
    Circulation; 2020 Jun; 141(22):1829-1831. PubMed ID: 32479195
    [No Abstract]   [Full Text] [Related]  

  • 4. Poststatin Lipid Therapeutics: A Review.
    Jia X; Lorenz P; Ballantyne CM
    Methodist Debakey Cardiovasc J; 2019; 15(1):32-38. PubMed ID: 31049147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention.
    Grundy SM; Stone NJ
    JAMA Cardiol; 2019 Jun; 4(6):589-591. PubMed ID: 30994869
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes.
    Ahangari N; Ghayour Mobarhan M; Sahebkar A; Pasdar A
    Ann Med; 2018 Jun; 50(4):303-311. PubMed ID: 29578362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Up to date lipid lowering treatment].
    Paragh G; Karádi I
    Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering.
    Rodriguez F; Harrington RA
    JAMA; 2016 Nov; 316(19):1967-1968. PubMed ID: 27838727
    [No Abstract]   [Full Text] [Related]  

  • 9. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.
    Sabatine MS; Giugliano RP
    JAMA Cardiol; 2017 Sep; 2(9):935-936. PubMed ID: 28768310
    [No Abstract]   [Full Text] [Related]  

  • 10. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
    O'Keefe JH; DiNicolantonio JJ; Lavie CJ
    Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 12. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
    Ortega Martínez de Victoria E
    Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
    [No Abstract]   [Full Text] [Related]  

  • 13. New Studies Do Not Challenge the American College of Cardiology/American Heart Association Lipid Guidelines.
    Hofer TP; Sussman JB; Hayward RA
    Ann Intern Med; 2016 May; 164(10):683-4. PubMed ID: 26857151
    [No Abstract]   [Full Text] [Related]  

  • 14. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care.
    Guglielmi V; Bellia A; Pecchioli S; Della-Morte D; Parretti D; Cricelli I; Medea G; Sbraccia P; Lauro D; Cricelli C; Lapi F
    Atherosclerosis; 2017 Aug; 263():36-41. PubMed ID: 28599257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
    Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration.
    Ference BA; Cannon CP; Landmesser U; Lüscher TF; Catapano AL; Ray KK
    Eur Heart J; 2018 Jul; 39(27):2540-2545. PubMed ID: 29020411
    [No Abstract]   [Full Text] [Related]  

  • 18. Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience.
    Gragnano F; Natale F; Concilio C; Fimiani F; Cesaro A; Sperlongano S; Crisci M; Limongelli G; Calabrò R; Russo M; Golia E; Calabrò P
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19(2):75-77. PubMed ID: 29251697
    [No Abstract]   [Full Text] [Related]  

  • 19. Maximizing the benefits of cholesterol-lowering drugs.
    Feingold KR
    Curr Opin Lipidol; 2019 Oct; 30(5):388-394. PubMed ID: 31335331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias.
    Packard CJ
    Curr Cardiol Rep; 2018 Jun; 20(8):60. PubMed ID: 29904807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.